Glenmark Pharmaceuticals Limited — Updates, 16-04-2025: Press Release

Glenmark Pharmaceuticals Inc., USA is set to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Tablets in various dosages (5 mg, 10 mg, 15 mg, 20 mg, and 30 mg), bioequivalent to the established Adderall® Tablets by Teva Women’s Health, Inc. Distribution is expected to begin in May 2025. Notably, the Adderall® market generated approximately $421.7 million in sales over the past year. This launch is particularly significant as it aims to alleviate the ongoing medication shortage in the U.S. market. With a heightened demand for these medications, Glenmark's entrance could positively influence its market positioning and revenue growth prospects. Investors should watch closely for the impact this new product will have on the company's performance.